Editorial
doi: 10.1016/j.jhep.2012.02.011.
Epub 2012 Mar 5.
TACE with or without systemic therapy?
- PMID: 22402292
- DOI: 10.1016/j.jhep.2012.02.011
Item in Clipboard
Editorial
TACE with or without systemic therapy?
J Hepatol.
2012 Jun.
Free article
No abstract available
Comment on
-
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.J Hepatol. 2012 Jun;56(6):1336-42. doi: 10.1016/j.jhep.2012.01.006. Epub 2012 Feb 4. J Hepatol. 2012. PMID: 22314421 Clinical Trial.
Similar articles
-
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335. Scand J Gastroenterol. 2010. PMID: 20113152 No abstract available.
-
Major achievements in hepatocellular carcinoma.Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. Lancet. 2009. PMID: 19231618 No abstract available.
-
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?J Gastroenterol Hepatol. 2011 Nov;26(11):1585-6. doi: 10.1111/j.1440-1746.2011.06901.x. J Gastroenterol Hepatol. 2011. PMID: 22011294 No abstract available.
-
[The treatment of hepatocellular carcinoma. New developments].Ned Tijdschr Geneeskd. 2009 Apr 4;153(14):668-72. Ned Tijdschr Geneeskd. 2009. PMID: 19425326 Review. Dutch. No abstract available.
-
Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.Crit Rev Oncol Hematol. 2012 Aug;83(2):216-24. doi: 10.1016/j.critrevonc.2011.10.008. Epub 2011 Dec 3. Crit Rev Oncol Hematol. 2012. PMID: 22142656 Review.
Cited by
-
Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.BMC Cancer. 2019 Apr 30;19(1):409. doi: 10.1186/s12885-019-5570-z. BMC Cancer. 2019. PMID: 31039750 Free PMC article.
-
CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling.Tumour Biol. 2014 Aug;35(8):7999-8005. doi: 10.1007/s13277-014-2000-3. Epub 2014 May 18. Tumour Biol. 2014. PMID: 24838946
-
Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.Cardiovasc Intervent Radiol. 2021 Sep;44(9):1394-1402. doi: 10.1007/s00270-021-02846-w. Epub 2021 May 4. Cardiovasc Intervent Radiol. 2021. PMID: 33948697 Free PMC article.
-
Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.Drug Des Devel Ther. 2022 Sep 30;16:3421-3429. doi: 10.2147/DDDT.S372276. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36203820 Free PMC article.
-
Current systemic treatment of hepatocellular carcinoma: A review of the literature.World J Hepatol. 2015 Jun 8;7(10):1412-20. doi: 10.4254/wjh.v7.i10.1412. World J Hepatol. 2015. PMID: 26052386 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
